Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Human Thromboxane A2 Receptor Genetic Variants: In Silico, In Vitro and “In Platelet” Analysis

  • Scott Gleim,

    Affiliation Internal Medicine, Cardiovascular Medicine, Yale University School of Medicine, New Haven Connecticut, United States of America

  • Jeremiah Stitham,

    Affiliation Internal Medicine, Cardiovascular Medicine, Yale University School of Medicine, New Haven Connecticut, United States of America

  • Wai Ho Tang,

    Affiliation Internal Medicine, Cardiovascular Medicine, Yale University School of Medicine, New Haven Connecticut, United States of America

  • Hong Li,

    Affiliation Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover New Hampshire, United States of America

  • Karen Douville,

    Affiliation Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover New Hampshire, United States of America

  • Prashen Chelikani,

    Affiliation Department of Oral Biology, University of Manitoba Faculty of Dentistry, Winnipeg, Manitoba, Canada

  • Jeffrey J.Rade,

    Affiliation Internal Medicine-Section of Cardiology, UMass School of Medicine and Medical Center, Worcester, Massachusetts, United States of America

  • Kathleen A. Martin,

    Affiliation Internal Medicine, Cardiovascular Medicine, Yale University School of Medicine, New Haven Connecticut, United States of America

  • John Hwa

    Affiliations Internal Medicine, Cardiovascular Medicine, Yale University School of Medicine, New Haven Connecticut, United States of America, Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover New Hampshire, United States of America


30 Jul 2013: Gleim S, Stitham J, Tang WH, Li H, Douville K, et al. (2013) Correction: Human Thromboxane A2 Receptor Genetic Variants: In Silico, In Vitro and “In Platelet” Analysis. PLOS ONE 8(7): 10.1371/annotation/83ddfba7-3c48-4c96-8cd1-0f0b5f69a5d1. View correction


Thromboxane and its receptor have emerged as key players in modulating vascular thrombotic events. Thus, a dysfunctional hTP genetic variant may protect against (hypoactivity) or promote (hyperactivity) vascular events, based upon its activity on platelets. After extensive in silico analysis, six hTP-α variants were selected (C68S, V80E, E94V, A160T, V176E, and V217I) for detailed biochemical studies based on structural proximity to key regions involved in receptor function and in silico predictions. Variant biochemical profiles ranged from severe instability (C68S) to normal (V217I), with most variants demonstrating functional alteration in binding, expression or activation (V80E, E94V, A160T, and V176E). In the absence of patient platelet samples, we developed and validated a novel megakaryocyte based system to evaluate human platelet function in the presence of detected dysfunctional genetic variants. Interestingly, variant V80E exhibited reduced platelet activation whereas A160T demonstrated platelet hyperactivity. This report provides the most comprehensive in silico, in vitro and “in platelet” evaluation of hTP variants to date and highlightscurrent inherent problems in evaluating genetic variants, with possible solutions. The study additionally provides clinical relevance to characterized dysfunctional hTP variants.


Cardiovascular disease and events affect nearly 80 million Americans, costing over $280 billion annually [1]. Landmark papers [2], [3] have demonstrated that COX-derived prostanoids (prostacyclin and thromboxane) significantly influence cardiovascular disease, with thromboxane promoting atherothrombotic events. Diabetes mellitus [4], [5], smoking [6], [7], [8], and obesity [9], [10] (key cardiovascular risk factors) are associated with increased thromboxane levels. Low dose aspirin, a cyclooxygenase inhibitor (COX-1>> COX-2), reduces platelet thromboxane production leading to protective effects in women (against strokes) and men (myocardial events) [11]. Moreover, selective COX-2 inhibitors suppress PGI2 production, abolishing its anti-atherothrombotic effect by allowing unrestricted thromboxane activity [2], [3]. These clinical findings have strong support from genetic deletion of the receptors for prostacyclin (IP) and thromboxane (TP) in mice [2], [3], [12]. Excess TxA2 signaling promote atherothrombosis.In contrast, deficient TxA2 signaling suppress atherothrombosis.

The human thromboxane A2 receptor (hTP) is a typical Class A rhodopsin-like G-protein coupled receptor. Despite being the first human eicosanoid receptor cloned [13], differential effects of hTP isoforms cloned from placenta (hTP alpha) and endothelium (hTP beta) [14] and their clinical importance highlight the need to better understand receptor structure and function [15], [16]. Mutational analysis of this receptor has identified a number of residues influencing binding [17], effector coupling [18], stability [19], and ligand recognition [20]. Thromboxane receptor variants are implicated in asthma susceptibility and severity [21], [22], [23], atopic dermatitis [24], and an autosomal dominant bleeding disorder [25].

We (and others) have identified a growing number of naturally occurring variants of the hTP receptor. Using predictive commonly used in silico algorithms in conjunction with molecular modeling we selected six variants to biochemically study. We also developed a functional assay to assess for platelet function conferred by the mutation. We report that two variants V80E and A160T have opposing roles on platelet activity, inhibiting and promoting platelet activation, respectively. In addition to the presentation and validation of a novel platelet based assay for the study of genetic variants, we highlight the poor predictive nature of some of the current, commonly used predictive algorithms for genetic variant and possible solutions.

Materials and Methods

Prediction of Variant Influence

Six polymorphism effect prediction algorithms were assessed to provide a view of expected outcomes based on differing methodology. Each algorithm utilizes protein sequence homology to some degree, with some incorporating physicochemical properties of side-chains (ProPhylER and Mutation Taster) or including structural annotations (SNPs3D and SNAP). The SIFT (Sorting Intolerant From Tolerant) algorithm ( [26] infers functional importance from sequence homology. Based on a PSI-BLAST search alignment, SIFT returns a scaled probability matrix for the likelihood of a protein to tolerate each of the twenty amino acids at each position in the protein. Output values for each amino acid change tolerance from SIFT ranges from 0 (damaging) to 1 (neutral). SNAP (screening for non-acceptable polymorphisms) ( [27] incorporates SIFT predictions along with PSI-BLAST alignment conservation, while incorporating additional sequence information including solvent accessibility and secondary structure (PROF), flexibility (PROFbval), and annotations from PMD (Protein Mutant Database) and. As with SIFT, SNAP reports a tolerance range from 0 (damaging) to 1 (neutral). PolyPhen (PPH) ( [28] has been superseded by PolyPhen-2 (PPH2) ( PolyPhen-2 provides two results based on HumVar (13,032 human disease causing mutations from UniProt and 8,946 human nonsynonymous single-nucleotide polymorphisms (nsSNPs) and HumDiv [29]. These prediction algorithms return a scaled probability from 0 (neutral) to >1 (damaging). The module of the SNPs3D resource ( [30] which focuses on predicting SNP influence on protein function, separately evaluates protein structural stability analysis and sequence conservation using a support vector machine approach trained on monogenic disease. ProPhylER ( [31] combines the physicochemical properties of amino acid side chains and the observed evolutionary variation of those properties to infer deleterious substitutions. The Grantham score [32] represents the original amino acid substitution scoring method, presenting a scale increasing from zero to indicate the degree of side-chain physicochemical difference between the original and mutant amino acid. Largely superseded by newer methodology, this value is still occasionally referenced, as shown by the most recently developed resource in this list, Mutation Taster. Mutation Taster ( [33] uses a naïve Bayes classifier to predict disease potential of an alteration. In addition, this method incorporates a prediction of potential changes in splice acceptor/donor probabilities (NNSplice).

Homology Model Construction

The human thromboxane A2 receptor (hTP) sequence was aligned with solved crystal structures, bovine rhodopsin (OPSD, UniProt P02699) and the human beta2-adrenergic receptor (ADRB2, UniProt P0755) in ClustalW. Both the PAM250 and BLOSUM algorithms indicated hTP to align more closely with OPSD (similarity score 30.16) than with ADRB2 (33.48). Each bundle of seven transmembrane α-helices was therefore based on a 2.8Å crystallographic bovine rhodopsin template (1HZX) using the internet-based protein-modeling server, SWISS-MODEL (GlaxoSmithKline, Geneva, Switzerland), and energy minimized using the Gromos96 force field in DeepView. Extracellular and cytoplasmic loop regions were manually constructed, built according to JPred consensus, and energy-minimized using the NAMD molecular dynamics simulator.

Biochemical and Pharmacological Analysis

Site-directed mutagenesis and transient transfections were performed on COS-1 cells as previously described [34]. Radioligand binding experiments (saturation and competition binding) [34] were then performed. IC50 values were converted to Ki using the Cheng-Prusoff equation, and values were expressed as a mean ± SE. For saturation binding experiments to determine Bmax and KD concentration of [3H] SQ-29548 was varied from 1 to 100 nM. Nonspecific binding was determined by the addition of a 500-fold excess of non-radiolabeled SQ-29548. Exponential decay rate constants (k) and half-lives were derived through nonlinear regression using Prism. A 95% confidence interval was used for all curve-fitting procedures using Prism.

[35S]GTPγS Thromboxane A2 Receptor Activation

Activity of hTP was measured by the accumulated incorporation of GTP analogue [35S]GTPγS (0.04 nM) into membrane preparations, following stimulation with 80 nM of synthetic TP agonist U-46619 (Sigma-Aldrich, St. Louis, MO). A concentration corresponding to the EC50 for aggregation of washed platelets [35]. Briefly, isolated membrane preparations were diluted in activity buffer (10 mM MgCl2 and 100 mM NaCl in 20 mM Hepes/Tris, pH 7.0) according to their BCA-measured protein concentration. An excess of guanosine diphosphate (GDP) was added (50 µM GDP) with or without addition of “cold” unlabeled GTPγs (10 µM), mixed with radiolabeled 5 nM [35S]GTPγs, and added to increasing concentrations of U-46619 in a 96 well plate. The plate was incubated for 2 hours at room temperature and quenched upon transfer to glass fiber filter papers with ice-cold 10 mM Tris-HCl. Filter-trapped radioactivity was quantified by liquid-scintillation counting.

Patient Recruitment and gDNA Sequencing

Patients were recruited from Dartmouth and John’s Hopkins as previously described, under protocols approved by their respective IRB [36] [34]. Presented in Table S1 are the cardiovascular risk profiles for each cohort. Genomic DNA was extracted (EDTA-anticoagulated blood) using the Puregene® system (Gentra Systems, Inc.). Samples were Sanger-sequenced for isoform-independent Exon 2, and hTP-α and hTP-β Exon 3 (Genbank NM001060 and NM201636, respectively).

Megakaryocyte Transfection and Flow Cytometry Measurement of Platelet-like Particle Activation

Transient transfection of Meg-01 cells (ATCC, Manassas, VA) was performed using the Nucleofection Kit C (Lonza, Walkersville, MD). The percentage of activated platelet-like particles was determined using two-color flow cytometry. Non-adherent cells and platelet-like particles were collected from megakaryocyte media 24 hours post Nucleofection, centrifuged at 1500 rpm for 10 minutes, and resuspended in PBS. Samples were treated with either 100 nM U46619 or equal volume of vehicle. Pelleted samples were resuspended, blocked with 3% BSA in PBS, pelleted again, and resuspended with phycoerythrin-labeled (PE) anti-CD42 and fluorescein isothiocyanate-labeled (FITC) anti-62p (P-Selectin) (BioLegend, San Diego, CA). Flow cytometric analyses were performed using a Becton-Dickinson FACSCalibur (Franklin Lakes, NJ). Twenty thousand events were recorded for each sample. In contrast to the [35S]GTPγS Thromboxane A2 Receptor Activation described above, we were additionally able to accurately measure basal activity, in part due in part to signaling amplification.

Statistical Analysis

Data was analyzed using GraphPad Prism® software (GraphPad Software, Inc., San Diego, CA). All means and SEM were calculated from at least three distinct experiments using separate protein preparations. Where applicable, statistical significance of the data was evaluated using an ANOVA and/or unpaired t test (*, p<0.05; **, p<0.01; ***, p<0.001). Analysis of variance (ANOVA) and student’s t tests were used to determine significant differences (p<0.05).


We hypothesized that hTP genetic variants may have a substantial modulatory effect on platelet activation.

In Silico Analysis: Discovery, Modeling, and Prediction

The in silico analysis consisted of three major components. There was an initial search (NCBI dbSNP) for hTP genetic variant. A homology model of the hTP was then developed to assess variants to pursue. Predictive algorithms were then used to calculate whether the variants would be functional.

At the beginning of our study, we identified 17 nonsynonomous genetic variants within the coding region (exons two and three) of the human thromboxane receptor from the dbSNP (Table 1), only 9 occured within the isoform-shared exon 2. Surprisingly, alignment analysis (PAM250 similarity matrix: 30.16 versus 33.48, respectively) determined hTP to be more similar in sequence and structure to bovine rhodopsin (UniProt P02699) than the human beta2-adrenergic receptor (UniProt P07550). The seven transmembrane (TM) bundle generated by Swiss-Model had minimal structural deviation from the reference model (2.8Å crystal structure of rhodopsin (1HZX) after minimization. Based upon this model we selected 6 novel mutations (Figure 1A) putatively involved in ligand selectivity (E94V, V176E in the extracellular - EC domain), ligand binding (V80G, A160T in the transmembrane-TM domain), receptor trafficking, and G-protein coupling (C68S, V217I towards the cytoplasmic-CYTO domain) (Figure 1A and 1B) for further analysis.

Figure 1. Structural Location of hTP Variants.

A. A two-dimensional secondary structure representation of the hTP indicating the position of the six non-synonymous (squares) genetic variants studied; in the extracellular region (E94V and V176E), in the upper transmembrane region (V80E and A160T), and at the cytoplasmic interface of the lower transmembrane region (C68S and V217I). B. Three dimensional homology modeling of the hTP receptor demonstrates the relative positions of these intriguing variants to occur in the ligand-recognition loop (E94V), in proximity to the structurally critical disulfide bond (V176E), lining the putative ligand binding pocket (V80E and A160T), and in proximity to the G-protein coupling site (C68S and V217I). These variants were evaluated in detail by molecular biological, biochemical, and pharmacological techniques.

Table 1. Non-synonomous Genetic Variants of the hTP Receptor from dbSNP.

Six commonly used predictive approaches were used to evaluate each of the six structurally diverse variants (Table 2). Interestingly, there were distinct discrepancies between some predictions (general disagreement between ProPhylER and PolyPhen2, as well as between SNPs3D and SIFT), but some were in agreement (Grantham and SIFT always agreed with each other, as did PolyPhen2 and MutationTaster) (Table 2). There was unanimous agreement amongst algorithms for only the V80E and V217I variants (Table 2).

In vitro Biochemical Analysis; Expression, Binding and Activation

Saturation binding, with antagonist SQ-29548, provides a quantative profile of receptor surface densities (Bmax, fmol/mg). C68S, V80E, E94V and V176E were significantly lower than wild-type, whereas A160T and V217I were not significantly different from wild type receptor (Figure 2A and 2B and Table 3). Competition binding provides high resolution binding affinities. While most of the variants display binding parameters similar to wild-type, the variants localized to the putative ligand binding region of the receptor, A160T and V80E, displayed increased or significantly decreased affinity, respectively (Figure 2C and Table 3). Molecular modeling of these site modifications suggested that the change of residue 160 from alanine to a threonine, disrupted the helical packing with transmembrane domain three (Figure 3). The larger charged side-chain of Glu80 likely protrudes into the putative ligand binding pocket, providing an explanation for the observed reduction in binding affinity.

Figure 2. Competition and Saturation Binding Analysis.

A. Saturation binding curves of hTP variants demonstrates a spectrum of binding deficits ranging from completely wild type (V217I) to severely dysfunctional (C68S). B. Histogram of the cell surface expression (Bmax) for each of the genetic variants analyzed. Significant differences from WT are highlighted (*p<0.05, **p<0.01, ***p<0.001). C. Competition binding of hTP variants demonstrates the relative affinity of antagonist for binding-competent receptors remains mostly normal. Statistically significant differences was observed only for A160T (increased affinity) and V80E (decreased affinity). D. GTPγS activation by hTP Variants upon treatment with TP agonist U-46619. Non-synonymous variants of hTP demonstrate different capacity to maximally stimulate effector signaling through GTPγs. The V217I, V176E, and E94V were indistinguishable from wild-type hTP receptor. Each of the other hTP genetic variants, C68S, V80E, and A160T, each demonstrate deficient effector activation with 80 nM U-46619 agonist stimulation. (*p<0.05, **p<0.01, ***p<0.001) Further details are provided in Table 3.

Figure 3. Binding Pocket Model of Disruption with Two hTP Variants.

A. A model of the wild-type binding pocket. The hTP receptor structure from the extracellular surface illustrates the putative binding pocket formed between the alpha helical bundles in the wild-type receptor. B. Binding pocket changes observed with the variants V80E, and A160T. Alteration of residue 80 to a glutamate shows an obstruction of the binding pocket by the protrusion of a charged side chain into the channel. Changing residue 160 to a threonine, on the other hand, results in a loss of interaction in the hydrophobic cluster.

Although the various naturally occurring genetic variants of the hTP receptor demonstrated a spectrum of dysfunctional binding and expression, the crucial measure of function is the ability of the formed receptor to couple to its cognate G-protein. Notable significant reductions in activation were found between the wild-type hTP receptor and the C68S, V80E, and A160T variants (Figure 2D and Table 3). A subsequent western analysis of the 5 dysfunctional mutations demonstrated robust expression of all the variants except for C68S, which we believe is unstable and rapidly degraded (Figure 4). This does not exclude other mechanisms such as improper processing of the transcript or inhibition of other events in biogenesis (e.g. translation). From these results, each variant clearly had distinct and divergent patterns of biochemical and pharmacological characteristics as summarized in Table 3.

Figure 4. Western Analysis of Dysfunctional Variants.

Western analysis for wild type hTP and the 5 dysfunctional mutations expressed in COS-1 cell membrane preparations. This was used to complement the saturation binding (folded protein) to assess for total cell surface expression (folded and misfolded). Monomers and oligomer formation is typical for GPCRs especially the misfolded variants. Shown are the approximate molecular weights in kD. The C68S demonstrated rapid degradation despite cocktails of protease inhibitors. This western analysis is representative of 4 performed.

Search for Dysfunctional Variants in Two High Thrombotic Risk Cohorts

Most dysfunctional variants are very rare, however we attempted to search for them in a high cardiovascular risk population. A high incidence of platelet rich arterial thrombotic events (strokes and heart attacks), can be found in such high cardiovascular risk populations with recognized atherosclerosis. We rationalized that we would find hTP variants in such high cardiovascular risk cohorts (hyperactivity variants having more disease and hypoactivity variants having less disease) and would be able to directly study receptor function in native platelets. We found three V217I (normal function) variants, and a number of synonomous variants (nucleotide change but no change in amino acid – Table 4) we did not find any of our dysfunctional variants in sequencing 897 high cardiovascular risk patients from two separate cohorts (Dartmouth and John’s Hopkin’s). These dysfunctional mutations may be protective against cardiovascular disease in a manner analogous to low dose aspirin (325 mg or less), which reduces thromboxane production and is cardioprotective. We excluded using a mouse model system as we and others have demonstrated that the thromboxane system in mice differs significantly from humans [36], [37], [38]. In the absence of direct patient samples we needed to develop a system to measure platelet activity in the presence of the genetic variants.

Table 4. Distribution of hTP Variants detected from sequencing two cohorts (n = 897).

“In Platelet” Functional Analysis

In the absence of patient samples in order to assess the downstream functional consequences, we needed a human platelet system that could be genetically modified. We discovered that a human megakaryocyte cell line (Meg-01) could be transfected and can produce platelet-like particles (PLP). We then verified whether thromboxane signaling in PLP reflected that of human platelets. We used a series of phosphoproteomic arrays to compare thromboxane signaling from PLP and human platelet rich plasma (PRP) (Figure 5A). There was remarkable similarity in the patterns of phosphorylation upon hTP stimulation (Figure 5A). As a control, prostacyclin signaling was clearly very different (Figure 5B). Our initial experiments with an RFP labeled hTP demonstrated abundant expression in the produced PLP (Figure 6A).

Figure 5. Development and Validation of Platelet Like Particle (PLP) System.

A. Phospho-proteomic array demonstrating signaling of thromboxane response (U-46619 -100 nM) in PRP and PLP. Each of three arrays was performed in duplicate. B. Prostacyclin receptor activation with iloprost (100 nM) is compared to that of thromboxane (U-46619–100 nM) demonstrating distinct differences in signaling.

Figure 6. hTP Functional Analysis in PLP.

A. Meg-01 Cells were nucleofected with hTP. Surface adherent megakaryocyte stained for p-Selectin (green) surrounded by produced platelet-like particles over-expressing nucleofected RFP-hTP-alpha. B. Stimulated display of CD62p (P-selectin) upon U-46619 treatment (100 nM) was reduced for the dysfunctional V80E variant, as well as completely unresponsive for the known bleeding variant R60L and D304N. Both baseline and stimulated levels of P-selectin were higher than wild type for the A160T variant, suggesting a considerable degree of constitutive activity. At least three independent repetitions were performed for each construct. Shown are mean ± SEM.

Individual variants that demonstrated signaling defects and were structurally stable (V80E and A160T) were then transfected into the Meg-01 cells and PLP collected for analysis. Wild type hTP transfection served as the negative control. As positive controls, we also reproduced two recently described hTP mutations that lead to a bleeding phenotype (R60L and D304N) [25], [39]. PLP were measured by flow cytometry for CD62p (P-selectin) exposure upon U46619 (thromboxane agonist) activation. Functional activation generally followed activity measured by effector coupling, with reduced activation by V80E variants (Figure 6B). The A160T variant, interestingly, showed higher baseline and stimulated activity than wild-type. This finding supports recent results suggesting a significant degree of constitutive activity for the A160T variant [40]. The V80E variant demonstrated dramatically reduced agonist response. Comparison of the V80E variant with known hTP bleeding variants (R60L and D304N) indicates that V80E retains some residual activity, and has a higher inherent baseline signal.

In order to assess clinical relevance, we performed an in vitro aspirin dose response on thromboxane production and aggregation, using in vitro doses determined to be equivalent to in vivo daily low dose aspirin (325 mg) as determined by Pedersen et. al. [41] We concluded that 325 mg of aspirin inhibited thromboxane-induced platelet activation to a similar extent as the D304N mutation (Figure 7). This finding is clinically important as it demonstrates that a dysfunctional hTP variant can confer a degree protection from platelet activation similar to the effect of low dose aspirin therapy in our PLP model, suggesting there may be a similar protective effect against cardiovascular disease in vivo. This will assist in identifying protective genetic variants that serve as protective “endogenous aspirin”. The V80E is currently the closest to D304N. This may explain in part the paucity of dysfunctional hTP genetic variants in the cardiovascular population as such mutations are protective against disease. However, the A160T, with its increased activity, should be enriched in such a cardiovascular population. The likely truth however are that these are very rare variants, found only in specific populations. Further independent large cardiovascular clinical cohort studies are required to determine whether this is the case.

Figure 7. Analysis of Low Dose (325 mg) Aspirin Effect.

In vitro aspirin dose response was performed for both aggregation and thromboxane production in human platelets (n = 4). The concentration equivalent to in vivo 325 mg aspirin (oral low dose aspirin) is indicated and the subsequent levels of thromboxane production and aggregation was calculated. This information was then used to determine which of the hTP mutation profiles best resembles that of “endogenous” low dose aspirin. This provides clinical and biochemical relevance to PLP results in the absence of patient samples.


Surprisingly little is known about the influence of hTP genetic variants on receptor structure/function and atherothrombotic disease. With TxA2 being a powerful airway constrictor, major pharmacogenetic research has focused on the association of variants with severity and susceptibility to asthma [22] [23] and atopic dermatitis [24]. However two recently discovered mutations have been reported to be associated with bleeding diathesis; an R60L in the first cytoplasmic loop [25] and D304N, in the GPCR-conserved NPXXY motif [42]. More recently, the structural basis for dysfunction was described for A160T [40]. There have additionally been a number of manuscripts describing variants of thromboxane synthase [43], [44], [45], but no data for cardiovascular disease association. We set out to assess hTP genetic variants using a combination of in silico, in vitro and “in platelet” approaches. We encountered many issues that are impeding the clinical progress of pharmacogenetics, including 1) poor predictive values from commonly used predictive algorithms, 2) heterogeneity of biochemical phenotypes and 3) studying extremely rare mutations. However, our studies have provided new insights into the hTP structure function relationship, and have led to a new genetic approach to study “in platelet” function.

Predictive Algorithms and Biochemical Phenotypes

With the enormous number of genetic variants that have been discovered, such algorithms, despite their limitations, can serve as a useful first pass analysis for detected variants; however, experimental receptor studies are mandatory. Variations in expression, binding, or activation require extensive in vitro testing. The functional defect can then be correlated to structural information. The development of such algorithms clearly needs to be informed by a team of structure/function experts in that particular class of proteins (e.g. GPCRs) in order to enhance accuracy.

Interestingly, each individual variant provided a unique signature of defects based in part on its localization within the protein structure in addition to the nature of the amino acid change. Such an understanding of the structural perturbation would be critically important for structurally based therapy. The A160T variant will likely require a negative agonist to dampen the enhanced basal activity. Furthermore, the affinity of the negative agonist would be required to be above that of thromboxane in order to effectively compete and prevent the functional hyperactivation. For V80E where binding affinity for thromboxane is severely impaired, possibly leading to bleeding, therapy may be needed to enhance thrombosis by targeting other receptors e.g. antagonizing the prostacyclin receptor. The C68S mutation may require ligands that help stabilize the receptor, preventing its rapid degradation. Thus, each mutation will require a distinctly different therapeutic approach.

Studying Patients with Rare Mutations

All the nonsynonomous mutations studied are rare mutations found in only select populations, thus making it difficult to directly assess their functional defects conferred on native platelets. Our Meg-01 cell system can effectively characterize their function. This was particularly important for A160T which exhibited reduced GTPγS activation in comparison to WT; however, on a background of high basal activity in the Meg-01 system there was clear overall hyperactivity. The use of known patient mutations with bleeding disorders helped in validating our assay and the calculation of the effects of low dose aspirin also improved the clinical utility of such an assay.

There are many significant limitations with the current study, the foremost of which is the lack of patient platelets to study. We have tried to overcome this with analysis in a platelet like particle system. A further limitation is the modeling of our studies on the crystal structure of rhodopsin, another GPCR. Ultimately, the ideal modeling would be based upon a crystal structure of the thromboxane receptor. Finally, the resources to study the thromboxane receptor pharmacologically (as we have performed here) are now extremely limited as the 3[H]-thromboxane ligands are no longer commercially available.

Our study comprises the most comprehensive in silico, biochemical and functional evaluation of hTP genetic variants to date, and demonstrates a range of biochemical and pharmacological receptor dysfunction imparted by hTP receptor variants. Such cross-disciplinary studies are needed if we are to incorporate genetic variants into clinical patient management.

Supporting Information

Table S1.

Populations of High-risk CVD Patients sequenced.


Author Contributions

Conceived and designed the experiments: SG JS WHT PC JR KM JH. Performed the experiments: SG JS WHT HL KD. Analyzed the data: SG JS WHT HL PC JR KM JH. Contributed reagents/materials/analysis tools: PC JR. Wrote the paper: SG JS WHT KM JH.


  1. 1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2012) Heart Disease and Stroke Statistics–2011 Update: A Report From the American Heart Association. Circulation 125(22): e1002.
  2. 2. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351: 1709–1711.
  3. 3. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539–541.
  4. 4. Ferroni P, Basili S, Falco A, Davi G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2: 1282–1291.
  5. 5. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, et al. (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322: 1769–1774.
  6. 6. Huang RY, Chen GG (2011) Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim Biophys Acta 15(2): 158–69.
  7. 7. Xie YH, Wang SW, Zhang Y, Edvinsson L, Xu CB (2010) Up-regulation of G-protein-coupled receptors for endothelin and thromboxane by lipid-soluble smoke particles in renal artery of rat. Basic Clin Pharmacol Toxicol 107: 803–812.
  8. 8. Calapai G, Caputi AP, Mannucci C, Gregg EO, Pieratti A, et al. (2009) A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol 21: 1138–1143.
  9. 9. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, et al. (2010) Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 13: 56–62.
  10. 10. Goodwill AG, James ME, Frisbee JC (2008) Increased vascular thromboxane generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with reduced oxygen tension. Am J Physiol Heart Circ Physiol 295: H1522–1528.
  11. 11. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293–1304.
  12. 12. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, et al. (2004) Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apo-E deficient mice. J Clin Invest 114: 784–794.
  13. 13. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, et al. (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349: 617–620.
  14. 14. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, et al. (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 269: 19256–19261.
  15. 15. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S (1996) Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97: 949–956.
  16. 16. Parent JL, Labrecque P, Orsini MJ, Benovic JL (1999) Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 274: 8941–8948.
  17. 17. Funk CD, Furci L, Moran N, Fitzgerald GA (1993) Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol 44: 934–939.
  18. 18. D'Angelo DD, Eubank JJ, Davis MG, Dorn GW 2nd (1996) Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J Biol Chem 271: 6233–6240.
  19. 19. Chiang N, Kan WM, Tai HH (1996) Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. Arch Biochem Biophys 334: 9–17.
  20. 20. Chiang N, Tai HH (1998) The role of N-glycosylation of human thromboxane A2 receptor in ligand binding. Arch Biochem Biophys 352: 207–213.
  21. 21. Hong SJ, Lee SY, Kim HB, Kim JH, Kim BS, et al. (2005) IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma. J Allergy Clin Immunol 115: 758–763.
  22. 22. Leung TF, Tang NL, Lam CW, Li AM, Chan IH, et al. (2002) Thromboxane A2 receptor gene polymorphism is associated with the serum concentration of cat-specific immunoglobulin E as well as the development and severity of asthma in Chinese children. Pediatr Allergy Immunol 13: 10–17.
  23. 23. Unoki M, Furuta S, Onouchi Y, Watanabe O, Doi S, et al. (2000) Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 106: 440–446.
  24. 24. Tanaka K, Roberts MH, Yamamoto N, Sugiura H, Uehara M, et al. (2002) Genetic variants of the receptors for thromboxane A2 and IL-4 in atopic dermatitis. Biochem Biophys Res Commun 292: 776–780.
  25. 25. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, et al. (1994) Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 94: 1662–1667.
  26. 26. Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Research 31: 3812–3814.
  27. 27. Bromberg Y, Rost B (2007) SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Research 35: 3823–3835.
  28. 28. Ramensky V, Bork P, Sunyaev S (2002) Human nonsynonymous SNPs: server and survey. Nucleic Acids Research 30: 3894–3900.
  29. 29. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Meth 7: 248–249.
  30. 30. Yue P, Melamud E, Moult J (2006) SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 22.
  31. 31. Binkley J, Karra K, Kirby A, Hosobuchi M, Stone E, et al. (2010) ProPhylER: A curated online resource for protein function and struction based on evolutionary constraint analyses. Genome Research 20: 142–154.
  32. 32. Grantham R (1974) Amino Acid Difference Formula to Help Explain Protein Evolution. Science 185: 862–864.
  33. 33. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Meth 7: 575–576.
  34. 34. Arehart E, Stitham J, Asselbergs FW, Douville K, MacKenzie T, et al. (2008) Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 102: 986–993.
  35. 35. Tymkewycz P, Jones R, Wilson N, Marr C (1991) Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Br J Pharmacol 102: 607–614.
  36. 36. Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, et al. (2011) Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 121: 4462–4476.
  37. 37. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS (1999) Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 81: 177–188.
  38. 38. Nunn B (1981) Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro. Thromb Haemost 45: 1–5.
  39. 39. Mumford AD, Dawood BB, Daly ME, Murden SL, Williams MD, et al. (2010) A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 115: 363–369.
  40. 40. Chakraborty R, Pydi SP, Gleim S, Dakshinamurti S, Hwa J, et al. (2012) Site-directed mutations and the polymorphic variant Ala160Thr in the human thromboxane receptor uncover a structural role for transmembrane helix 4. PLoS One 7: e29996.
  41. 41. Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311: 1206–1211.
  42. 42. Mumford AD, Dawood BB, Daly ME, Murden SL, Williams MD, et al. (2010) A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 115: 363–369.
  43. 43. Ulrich CM, Carlson CS, Sibert J, Poole EM, Yu JH, et al. (2005) Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 26: 394–395.
  44. 44. Chevalier D, Lo-Guidice JM, Sergent E, Allorge D, Debuysere H, et al. (2001) Identification of genetic variants in the human thromboxane synthase gene (CYP5A1). Mutat Res 432: 61–67.
  45. 45. Baek SJ, Lee KD, Shen RF (1996) Genomic structure and polymorphism of the human thromboxane synthase-encoding gene. Gene 173: 251–256.